Structure Therapeutics Inc (GPCR)

$71.56 +1.49 (2.13%)
Market Cap 4.25B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 676,180
Avg Vol 1,655,514
Day's Range N/A - N/A
Shares Out 60.68M
Stochastic %K 1%
Beta -2.06
Analysts Strong Sell
Price Target $107.80

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
judgeyoung2
judgeyoung2 Feb. 17 at 1:38 PM
$GPCR so i’m guessing all buyout talks from JPM fell through
0 · Reply
keylimepie2
keylimepie2 Feb. 12 at 6:24 PM
$VKTX Nice try.. 1. Viking is as close if not closer to market than $GPCR 2. It has multiple formulations vs just a single asset 3. The assets appear to have better efficacy and tolerability
1 · Reply
blocktrade
blocktrade Feb. 12 at 3:01 PM
$GPCR stupid sell off also 48k shares traded?
0 · Reply
biolover
biolover Feb. 12 at 2:46 PM
$VKTX look at $GPCR volume ? Vk shorts busy trying to cut losses. Dont have time for anyone else 😂
0 · Reply
keylimepie2
keylimepie2 Feb. 12 at 12:53 PM
Kyle is now fully OTM on his $32 $VKTX puts and $80 $GPCR calls expiring this week.
0 · Reply
Quantumup
Quantumup Feb. 12 at 10:37 AM
Laidlaw reiterated $VKTX Buy/$110: $NVO $GPCR LLY AMGN PFE Morgan Stanley⬇️the PT to $99 from $102 and reiterated at Overweight: Here's what Laidlaw and Morgan Stanley had to say in their notes to investors: https://x.com/Quantumup1/status/2021895256011145704?s=20
0 · Reply
Lixothetinman
Lixothetinman Feb. 11 at 10:43 PM
$GPCR poor Kylenorth. Too busy pumping and bashing instead of DDing.
0 · Reply
keylimepie2
keylimepie2 Feb. 11 at 10:33 PM
$VKTX So oral VK2735 will actually beat $GPCR to the market?? On top of the BIC SC GLP?? Oh yeah shorts are fucked. But also $GPCR could get hit really hard with this news.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 11 at 8:19 PM
$GPCR Share Price: $76.26 Contract Selected: Jul 17, 2026 $80 Calls Buy Zone: $10.20 – $12.60 Target Zone: $18.09 – $22.11 Potential Upside: 67% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
aga5757st
aga5757st Feb. 11 at 4:40 PM
$GPCR Having lived a lifetime in PHARMA, these convos remind of a key ACTION directive from William Wallace (e.g. Mel Gipson) in Braveheart. The docu-drama scene of the Battle of Stirling, where he tells his Scottish army of many commoners, to "HOLD. HOLD. HOLD......." But you do what you want with your particular schiltron.
0 · Reply
Latest News on GPCR
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 14 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 27 days ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 4 weeks ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 2 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 2 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 9, 2025, 8:30 AM EST - 2 months ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 7:27 PM EST - 2 months ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 5:18 PM EST - 2 months ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 2 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 12:46 PM EST - 2 months ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 2 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 2 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 2 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 2 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 3 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 3 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 5 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 6 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 8 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 8 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 11 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 11 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 11 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 11 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 11 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

judgeyoung2
judgeyoung2 Feb. 17 at 1:38 PM
$GPCR so i’m guessing all buyout talks from JPM fell through
0 · Reply
keylimepie2
keylimepie2 Feb. 12 at 6:24 PM
$VKTX Nice try.. 1. Viking is as close if not closer to market than $GPCR 2. It has multiple formulations vs just a single asset 3. The assets appear to have better efficacy and tolerability
1 · Reply
blocktrade
blocktrade Feb. 12 at 3:01 PM
$GPCR stupid sell off also 48k shares traded?
0 · Reply
biolover
biolover Feb. 12 at 2:46 PM
$VKTX look at $GPCR volume ? Vk shorts busy trying to cut losses. Dont have time for anyone else 😂
0 · Reply
keylimepie2
keylimepie2 Feb. 12 at 12:53 PM
Kyle is now fully OTM on his $32 $VKTX puts and $80 $GPCR calls expiring this week.
0 · Reply
Quantumup
Quantumup Feb. 12 at 10:37 AM
Laidlaw reiterated $VKTX Buy/$110: $NVO $GPCR LLY AMGN PFE Morgan Stanley⬇️the PT to $99 from $102 and reiterated at Overweight: Here's what Laidlaw and Morgan Stanley had to say in their notes to investors: https://x.com/Quantumup1/status/2021895256011145704?s=20
0 · Reply
Lixothetinman
Lixothetinman Feb. 11 at 10:43 PM
$GPCR poor Kylenorth. Too busy pumping and bashing instead of DDing.
0 · Reply
keylimepie2
keylimepie2 Feb. 11 at 10:33 PM
$VKTX So oral VK2735 will actually beat $GPCR to the market?? On top of the BIC SC GLP?? Oh yeah shorts are fucked. But also $GPCR could get hit really hard with this news.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 11 at 8:19 PM
$GPCR Share Price: $76.26 Contract Selected: Jul 17, 2026 $80 Calls Buy Zone: $10.20 – $12.60 Target Zone: $18.09 – $22.11 Potential Upside: 67% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
aga5757st
aga5757st Feb. 11 at 4:40 PM
$GPCR Having lived a lifetime in PHARMA, these convos remind of a key ACTION directive from William Wallace (e.g. Mel Gipson) in Braveheart. The docu-drama scene of the Battle of Stirling, where he tells his Scottish army of many commoners, to "HOLD. HOLD. HOLD......." But you do what you want with your particular schiltron.
0 · Reply
JonathanV
JonathanV Feb. 10 at 10:10 PM
$GPCR No PRs since Dec-17. I like it. They must be busy 😊
0 · Reply
Kylenorth
Kylenorth Feb. 10 at 3:14 PM
$GPCR PAY ME!!!!
1 · Reply
norbertm
norbertm Feb. 10 at 2:43 PM
$GPCR maybe also a good idea to tag $VKTX
0 · Reply
norbertm
norbertm Feb. 10 at 1:47 PM
$GPCR PM drop possibly related to this: https://x.com/doepke_michel/status/2021193533676257667
0 · Reply
Kylenorth
Kylenorth Feb. 9 at 8:53 PM
$GPCR just pay me my money!!! what a runner
0 · Reply
Kylenorth
Kylenorth Feb. 9 at 4:43 PM
$GPCR here we go!! always follow the big money!!!
0 · Reply
Bizzonaci
Bizzonaci Feb. 9 at 4:31 PM
$GPCR averaged up today this will be taken out
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 8 at 1:39 PM
$NVO CEO throws shade at Pfizer for overpaying for Metsera, and admits they’re looking for “deals”. Both $ALT & $VKTX are likely takeout candidates in this space. $GPCR too ⏰ “We need … multiples of different assets to deal with the diversity of the patient population that these two therapy areas entail,” the CEO said. “Many of those solutions we have in-house … but we will also continue looking outside and see what has been made by others that complements what we have in our pipeline.” https://www.fiercebiotech.com/biotech/novos-ceo-wishes-pfizer-luck-metsera-drug-still-seeks-own-monthly-glp-1
2 · Reply
Kylenorth
Kylenorth Feb. 6 at 9:11 PM
$GPCR buying a ton of next weeks 80 calls!! going to moon!!!
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 5 at 7:31 PM
$VKTX $GPCR $LLY $NVO tough day in the stock market and obesity stocks are getting beat up. vktx looking more and more attractive at current mc.
0 · Reply
CattleFarmerJ
CattleFarmerJ Feb. 4 at 4:05 PM
$GPCR act like retail get treated like retail. You cant stomach a little movement this game isnt for you. Stop crying BO or not every bank and fund target is 125+
0 · Reply
Pajohnamo
Pajohnamo Feb. 4 at 3:12 PM
$GPCR give us the buy out
0 · Reply